Avalyn Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Selling, General & Admin	18.97	14.68	9.96
Research & Development	91.03	76.61	45.76
Operating Expenses	110	91.29	55.72
Operating Income	-110	-91.29	-55.72
Interest & Investment Income	7.12	6.18	7.44
Other Non Operating Income (Expenses)	-0.07	-0.09	-0.02
EBT Excluding Unusual Items	-103.31	-85.2	-48.3
Gain (Loss) on Sale of Assets	-	-	-0.05
Legal Settlements	-	-	-1.4
Pretax Income	-103.31	-85.2	-49.74
Net Income	-103.31	-85.2	-49.74
Net Income to Common	-103.31	-85.2	-49.74
Net Income Growth	-	-	-
Shares Outstanding (Basic)	8	1	0
Shares Outstanding (Diluted)	8	1	0
Shares Change	-	259.46%	-
EPS (Basic)	-12.34	-87.74	-184.14
EPS (Diluted)	-12.34	-87.74	-184.14
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-98.4	-81.83	-48.46
Free Cash Flow Per Share	-11.75	-84.27	-179.40
EBITDA	-109.8	-91.25	-55.69
D&A For EBITDA	0.2	0.04	0.03
EBIT	-110	-91.29	-55.72

SEC Filings: 10-K · 10-Q